Eton Pharmaceuticals (NASDAQ:ETON) Given New $11.00 Price Target at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its target price boosted by HC Wainwright from $9.00 to $11.00 in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at $0.12 EPS, Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.16 EPS and Q4 2025 earnings at $0.18 EPS.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $7.30 on Friday. The firm has a market capitalization of $187.54 million, a PE ratio of 182.50 and a beta of 1.31. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $7.66. The stock has a fifty day moving average of $4.78 and a two-hundred day moving average of $3.96.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The company had revenue of $9.07 million during the quarter, compared to the consensus estimate of $10.00 million. Equities research analysts predict that Eton Pharmaceuticals will post -0.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Eton Pharmaceuticals

In other news, major shareholder Opaleye Management Inc. bought 57,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average price of $4.65 per share, with a total value of $267,375.00. Following the completion of the purchase, the insider now directly owns 2,660,000 shares of the company’s stock, valued at $12,369,000. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 14.89% of the stock is currently owned by corporate insiders.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Opaleye Management Inc. grew its holdings in shares of Eton Pharmaceuticals by 4.1% in the 4th quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after acquiring an additional 99,617 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in Eton Pharmaceuticals during the second quarter valued at about $3,095,000. Westside Investment Management Inc. boosted its position in shares of Eton Pharmaceuticals by 2.0% in the second quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after buying an additional 11,440 shares during the period. Aristides Capital LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at $658,000. Finally, Acadian Asset Management LLC lifted its stake in Eton Pharmaceuticals by 13.7% in the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after acquiring an additional 18,898 shares in the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.